A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors
This Study is
No Longer Enrolling
Details
Age
Adult
Eligibility
patients must have germline or somatic mutation in DDR genes, actionable mutation in PTEN gene or hotspot mutation in the PIK3CA gene
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 19-1987
More information available at ClinicalTrials.gov: NCT03842228
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers